Helius Medical Technologies Inc announces that the United States Patent and Trademark Office has issued US Patent No. 11,197,994, which is directed to systems for providing non-invasive neurorehabilitation of a patient.

The patent is similar in scope to prior Helius patents for the Portable Neuromodulation Stimulator (PoNS) device but expressly recites that the communications between the mouthpiece and controller are done wirelessly.

“We are pleased to announce our new patent, which will allow for a wireless connection between the mouthpiece and controller of our PoNS device. PoNS is the first and only patented therapy combining trigeminal nerve neurostimulation via the tongue with physical therapy to reduce symptoms of neurological disease or trauma, and this patent is an important building block for future generations of PoNS therapy.”

Dane Andreeff, President and Chief Executive Officer of Helius

Helius now owns 34 US and 46 foreign patents expiring between 2026 and 2036, and exclusively licenses nine US medical method patents expiring between 2029 and 2031.

[Source(s): Helius Medical Technologies Inc, GlobeNewswire]